h186d heterozygous mutation in the kcnj11 gene whose treatment was successfully transitioned from insulin to oral sulfonylurea. her parents were unrelated , and her family was healthy and had no history of diabetes. 025 ; hco3 , 5. although there were several hypoglycemic events , insulin injection for glucose control after the infancy period could not be stopped. transition of treatment from insulin to sulfonylurea was attempted at the age of 4. 2 cm in height ( 25th50th percentile ) , 17 kg in weight ( 50th75th percentile ) and did not have any specific neurological deficit. the patient is now 7.h186d heterozygous mutation in the kcnj11 gene whose treatment was successfully transitioned from insulin to oral sulfonylurea. her parents were unrelated , and her family was healthy and had no history of diabetes. 025 ; hco3 , 5. although there were several hypoglycemic events , insulin injection for glucose control after the infancy period could not be stopped. transition of treatment from insulin to sulfonylurea was attempted at the age of 4. 2 cm in height ( 25th50th percentile ) , 17 kg in weight ( 50th75th percentile ) and did not have any specific neurological deficit. the patient is now 7.